Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases

Clinical Chemistry

Volumn 56, Issue 12, 2010, Pages 1830-1838

  Zhang, Yi ^a   Jia, Yin ^a   Zheng, Ruiying ^b   Guo, Yingjun ^a   Wang, Yue ^a   Guo, Hui ^c   Fei, Mingyu ^a   Sun, Shuhan ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c BENGBU MEDICAL COLLEGE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BIOLOGICAL MARKER; GALACTOSAMINE; MICRORNA; MICRORNA 122; UNCLASSIFIED DRUG;

ADULT; ALCOHOL LIVER DISEASE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; HEPATITIS B; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MYOPATHY; REAL TIME POLYMERASE CHAIN REACTION; RELIABILITY; VALIDATION PROCESS; VIRUS HEPATITIS;

ADULT; ALANINE TRANSAMINASE; ANIMALS; BIOLOGICAL MARKERS; DRUG-INDUCED LIVER INJURY; ETHANOL; FEMALE; GALACTOSAMINE; HEPATITIS B, CHRONIC; HUMANS; LIVER DISEASES; MALE; MICE; MICE, INBRED BALB C; MICRORNAS; MUSCLE, SKELETAL; PLASMA;

ANIMALIA;

EID: 78649837734     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2010.147850     Document Type: Article

References (34)

1. Kim WR, Flamm SL, Di Bisceglie AM, Bodenheimer HC, on behalf of the Public Policy Committee of the American Association for the Study of Liver Disease. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology 2008;47:1363-70.
2. Nathwani RA, Pais S, Reynolds TB, Kaplowitz N. Serum alanine aminotransferase in skeletal muscle diseases. Hepatology 2005;41:380-2.
3. Shabaneh Al-Tamimi HA, McDonald R. Elevated alanine aminotransferase levels associated with polymyositis: Can this be due to muscle injury? J Clin Rheumatol 2008;14:363-4.
4. Ozer J, Ratner M, Shaw M, Bailey W, Schomaker S. The current state of serum biomarkers of hepatotoxicity. Toxicology 2008;245:194-205.
5. Amacher DE, Adler R, Herath A, Townsend RR. Use of proteomic methods to identify serum biomarkers associated with rat liver toxicity or hypertrophy. Clin Chem 2005;51:1796-803.
6. Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell 2009;136: 642-55.
7. Williams AE. Functional aspects of animal microRNAs. Cell Mol Life Sci 2008;65:545-62.
8. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 2009; 27:5848-56.
9. Schepeler T, Reinert JT, Ostenfeld MS, Christensen LL, Silahtaroglu AN, Dyrskjøt L, et al. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 2008;68:6416-24.
10. Bartels CL, Tsongalis GJ. MicroRNAs: novel biomarkers for human cancer. Clin Chem 2009; 55:623-31.
11. Vasilescu C, Rossi S, Shimizu M, Tudor S, Veronese A, Ferracin M, et al. MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis. PLoS One 2009; 4:e7405.
12. Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009;58:1375-81.
13. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, Kerin MJ. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg 2010;251:499-505.
14. Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J, et al. Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 2010;31:659-66.
15. Laterza OF, Lim L, Garrett-Engele PW, Vlasakova K, Muniappa N, Tanaka WK, et al. Plasma microRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem 2009;55:1977-83.
16. Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A 2009;106:4402-7.
17. Nakama T, Hirono S, Moriuchi A, Hasuike S, Nagata K, Hori T, et al. Etoposide prevents apoptosis in mouse liver with D-galactosamine/ lipopolysaccharide-induced fulminant hepatic failure resulting in reduction of lethality. Hepatology 2001;33:1441-50.
18. Zhao J, Chen H, Li Y. Protective effect of bicyclol on acute alcohol-induced liver injury in mice. Eur J Pharmacol 2008;586:322-31.
19. Chim SS, Shing TK, Hung EC, Leung TY, Lau TK, Chiu RW, Lo YM. Detection and characterization of placental microRNAs in maternal plasma. Clin Chem 2008;54:482-90.
20. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19:1513-20. (Pubitemid 24166476)
21. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9.
22. Barad O, Meiri E, Avniel A, Aharonov R, Barzilai A, Bentwich I, et al. MicroRNA expression detected by oligonucleotide microarrays: system establishment and expression profiling in human tissues. Genome Res 2004;14:2486-94.
23. Girard M, Jacquemin E, Munnich A, Lyonnet S, Henrion-Caude A. miR-122, a paradigm for the role of microRNAs in the liver. J Hepatol 2008; 48:648-56.
24. Liang Y, Ridzon D, Wong L, Chen C. Characterization of microRNA expression profiles in normal human tissues. BMC Genomics 2007;8:166.
25. Chang J, Nicolas E, Marks D, Sander C, Lerro A, Buendia MA, et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol 2004;1: 106-13.
26. Leman ES, Schoen RE, Weissfeld JL, Cannon GW, Sokoll LJ, Chan DW, Getzenberg RH. Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers. Cancer Res 2007;67:5600-5.
27. Ebert MP, Korc M, Malfertheiner P, Röcken C. Advances, challenges, and limitations in serumproteome- based cancer diagnosis. J Proteome Res 2006;5:19-25.
28. Wong SC, Chan CM, Ma BB, Lam MY, Choi GC, Au TC, et al. Advanced proteomic technologies for cancer biomarker discovery. Expert Rev Proteomics 2009;6:123-34.
29. Dennis Lo YM, Chiu RW. Prenatal diagnosis: progress through plasma nucleic acids. Nat Rev Genet 2007;8:71-7.
30. Chan KC, Lo YM. Circulating tumour-derived nucleic acids in cancer patients: potential applications as tumour markers. Br J Cancer 2007;96: 681-5.
31. Lo YM, Chan LY, Lo KW, Leung SF, Zhang J, Chan AT, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999;59: 1188-91.
32. Wong SC, Lo SF, Cheung MT, Ng KO, Tse CW, Lai BS, et al. Quantification of plasma beta-catenin mRNA in colorectal cancer and adenoma patients. Clin Cancer Res 2004;10:1613-7.
33. Silva JM, Rodriguez R, Garcia JM, Muñoz C, Silva J, Dominguez G, et al. Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells. Gut 2002;50:530-4.
34. Chen XQ, Bonnefoi H, Pelte MF, Lyautey J, Lederrey C, Movarekhi S, et al. Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin Cancer Res 2000;6:3823-6.